Foghorn Therapeutics (FHTX) Competitors $5.19 -0.09 (-1.70%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.18 -0.01 (-0.10%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. PHVS, RCUS, ZYME, GPCR, CRMD, LENZ, SION, STOK, MLYS, and PHARShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Pharvaris (PHVS), Arcus Biosciences (RCUS), Zymeworks (ZYME), Structure Therapeutics (GPCR), CorMedix (CRMD), LENZ Therapeutics (LENZ), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), Mineralys Therapeutics (MLYS), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Its Competitors Pharvaris Arcus Biosciences Zymeworks Structure Therapeutics CorMedix LENZ Therapeutics Sionna Therapeutics Stoke Therapeutics Mineralys Therapeutics Pharming Group Pharvaris (NASDAQ:PHVS) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations. Which has more volatility & risk, PHVS or FHTX? Pharvaris has a beta of -2.8, meaning that its share price is 380% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500. Is PHVS or FHTX more profitable? Pharvaris has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -311.90%. Foghorn Therapeutics' return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -69.09% -63.34% Foghorn Therapeutics -311.90%N/A -28.00% Do analysts rate PHVS or FHTX? Pharvaris currently has a consensus price target of $34.00, indicating a potential upside of 46.55%. Foghorn Therapeutics has a consensus price target of $10.67, indicating a potential upside of 105.52%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.17 Which has better valuation and earnings, PHVS or FHTX? Foghorn Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$145.24M-$3.36-6.90Foghorn Therapeutics$24.17M12.14-$86.62M-$1.19-4.36 Do institutionals & insiders have more ownership in PHVS or FHTX? 61.5% of Foghorn Therapeutics shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor PHVS or FHTX? In the previous week, Pharvaris had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Pharvaris and 2 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.76 beat Pharvaris' score of 0.98 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Foghorn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryFoghorn Therapeutics beats Pharvaris on 12 of the 16 factors compared between the two stocks. Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$293.39M$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-4.3621.4375.4125.98Price / Sales12.14429.44515.81181.13Price / CashN/A46.6837.5660.44Price / Book-6.339.6112.156.29Net Income-$86.62M-$53.29M$3.29B$271.07M7 Day Performance-10.05%0.13%0.74%3.87%1 Month Performance0.97%5.55%5.00%5.49%1 Year Performance-46.60%10.44%62.53%25.86% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.7683 of 5 stars$5.19-1.7%$10.67+105.5%-46.6%$293.39M$24.17M-4.36120Positive NewsPHVSPharvaris2.2171 of 5 stars$21.65-5.2%$35.60+64.4%+10.9%$1.13BN/A-6.4430RCUSArcus Biosciences2.0375 of 5 stars$10.60-0.1%$21.14+99.6%-36.0%$1.13B$258M-3.34500Positive NewsZYMEZymeworks0.0334 of 5 stars$14.81-0.2%N/AN/A$1.11B$76.30M-15.27460GPCRStructure Therapeutics3.4839 of 5 stars$19.30+0.8%$75.71+292.3%-48.8%$1.11BN/A-18.38136News CoveragePositive NewsAnalyst RevisionCRMDCorMedix3.9089 of 5 stars$14.83+3.3%$17.33+16.9%+86.2%$1.11B$43.47M19.7730Trending NewsAnalyst ForecastInsider TradeShort Interest ↑LENZLENZ Therapeutics1.6304 of 5 stars$38.63+1.1%$49.60+28.4%+89.1%$1.10BN/A-20.33110Positive NewsSIONSionna Therapeutics2.8052 of 5 stars$24.62-4.3%$38.50+56.4%N/A$1.09BN/A0.0035Gap UpSTOKStoke Therapeutics3.9399 of 5 stars$19.76-0.1%$25.57+29.4%+62.1%$1.08B$36.56M23.25100Positive NewsMLYSMineralys Therapeutics3.1517 of 5 stars$15.48+1.7%$34.40+122.2%+215.5%$1.03BN/A-4.3528Positive NewsAnalyst ForecastPHARPharming Group2.2414 of 5 stars$14.84+1.7%$30.00+102.2%+95.7%$1.02B$297.20M-114.15280News CoverageShort Interest ↑ Related Companies and Tools Related Companies Pharvaris Competitors Arcus Biosciences Competitors Zymeworks Competitors Structure Therapeutics Competitors CorMedix Competitors LENZ Therapeutics Competitors Sionna Therapeutics Competitors Stoke Therapeutics Competitors Mineralys Therapeutics Competitors Pharming Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FHTX Stock Alerts